Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis

Optimal management of clinical stage IIIA (N2) non-small cell lung cancer (NSCLC) is controversial. This study is a systematic review and meta-analysis of published randomized control trials of multimodality management strategies for NSCLC. We conducted a comprehensive literature search of the Pubme...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ya-Ping, Li, Bo, Xu, Xiao-Ling, Mao, Wei-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616485/
https://www.ncbi.nlm.nih.gov/pubmed/26061306
http://dx.doi.org/10.1097/MD.0000000000000879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616485/
https://www.ncbi.nlm.nih.gov/pubmed/26061306
http://dx.doi.org/10.1097/MD.0000000000000879

Ejemplares similares